259 related articles for article (PubMed ID: 20504344)
1. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.
Ferracin M; Zagatti B; Rizzotto L; Cavazzini F; Veronese A; Ciccone M; Saccenti E; Lupini L; Grilli A; De Angeli C; Negrini M; Cuneo A
Mol Cancer; 2010 May; 9():123. PubMed ID: 20504344
[TBL] [Abstract][Full Text] [Related]
2. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.
Moussay E; Palissot V; Vallar L; Poirel HA; Wenner T; El Khoury V; Aouali N; Van Moer K; Leners B; Bernardin F; Muller A; Cornillet-Lefebvre P; Delmer A; Duhem C; Ries F; van Dyck E; Berchem G
Mol Cancer; 2010 May; 9():115. PubMed ID: 20487546
[TBL] [Abstract][Full Text] [Related]
3. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
[TBL] [Abstract][Full Text] [Related]
5. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.
Rossi D; Fangazio M; Rasi S; Vaisitti T; Monti S; Cresta S; Chiaretti S; Del Giudice I; Fabbri G; Bruscaggin A; Spina V; Deambrogi C; Marinelli M; Famà R; Greco M; Daniele G; Forconi F; Gattei V; Bertoni F; Deaglio S; Pasqualucci L; Guarini A; Dalla-Favera R; Foà R; Gaidano G
Blood; 2012 Mar; 119(12):2854-62. PubMed ID: 22308293
[TBL] [Abstract][Full Text] [Related]
6. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.
Zhu DX; Zhu W; Fang C; Fan L; Zou ZJ; Wang YH; Liu P; Hong M; Miao KR; Liu P; Xu W; Li JY
Carcinogenesis; 2012 Jul; 33(7):1294-301. PubMed ID: 22610076
[TBL] [Abstract][Full Text] [Related]
7. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
9. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
10. Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances.
Perez-Chacon G; Martinez-Laperche C; Rebolleda N; Somovilla-Crespo B; Muñoz-Calleja C; Buño I; Zapata JM
Clin Cancer Res; 2016 Jan; 22(1):134-45. PubMed ID: 26324744
[TBL] [Abstract][Full Text] [Related]
11. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
12. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.
Morales AA; Olsson A; Celsing F; Osterborg A; Jondal M; Osorio LM
Int J Cancer; 2005 Feb; 113(5):730-7. PubMed ID: 15499630
[TBL] [Abstract][Full Text] [Related]
13. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
[TBL] [Abstract][Full Text] [Related]
14. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
[TBL] [Abstract][Full Text] [Related]
15. DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Grgurevic S; Montilla-Perez P; Bradbury A; Gilhodes J; Queille S; Pelofy S; Bancaud A; Filleron T; Ysebaert L; Récher C; Laurent G; Fournié JJ; Cazaux C; Quillet-Mary A; Hoffmann JS
Haematologica; 2018 Jun; 103(6):1038-1046. PubMed ID: 29567785
[TBL] [Abstract][Full Text] [Related]
16. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.
Mackey JR; Galmarini CM; Graham KA; Joy AA; Delmer A; Dabbagh L; Glubrecht D; Jewell LD; Lai R; Lang T; Hanson J; Young JD; Merle-Béral H; Binet JL; Cass CE; Dumontet C
Blood; 2005 Jan; 105(2):767-74. PubMed ID: 15454483
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
Ashofteh N; Amini R; Molaee N; Karami H; Baazm M
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2191-2198. PubMed ID: 34319043
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
